Jennifer R. Wortman, PhD

Vice President, Clinical Discovery and Research Technologies
Seres Therapeutics

Poster(s):

• 027: Engraftment of Investigational Microbiome Therapeutic SER-109 is Durable Through 24 Weeks in a Randomized Trial (ECOSPOR III) for the Treatment of Recurrent Clostridioides Difficile Infection
  Monday, September 26, 2022

  5:00 PM – 7:00 PM ET